Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Cantor Fitzgerald
Teva
Federal Trade Commission
Colorcon
Johnson and Johnson
Farmers Insurance
Argus Health
Daiichi Sankyo
Fuji

Generated: February 18, 2018

DrugPatentWatch Database Preview

Claims for Patent: 7,700,550

« Back to Dashboard

Summary for Patent: 7,700,550
Title:Glycopeptide phosphonate derivatives
Abstract:Disclosed are glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents.
Inventor(s): Leadbetter; Michael R. (San Leandro, CA)
Assignee: Theravance, Inc. (South San Francisco, CA)
Application Number:11/977,429
Patent Claims: 1. A method for treating a bacterial infection in a human, the method comprising administering to the human a compound of the formula: ##STR00009## or a pharmaceutically acceptable salt thereof.

2. The method of claim 1, wherein the compound is a hydrochloride salt.

3. The method of claim 1, wherein the compound or a pharmaceutically acceptable salt thereof is administered intravenously.

4. The method of claim 1, wherein the compound or a pharmaceutically acceptable salt thereof is administered once per day.

5. A method for treating a staphylococcal infection in a human, the method comprising administering to the human a compound of the formula: ##STR00010## or a pharmaceutically acceptable salt thereof.

6. The method of claim 5, wherein the compound is a hydrochloride salt.

7. The method of claim 5, wherein the compound or a pharmaceutically acceptable salt thereof is administered intravenously.

8. The method of claim 5, wherein the compound or a pharmaceutically acceptable salt thereof is administered once per day.

9. The method of claim 5, wherein the staphylococcal infection is caused by Staphylococcus aureus.

10. The method of claim 5, wherein the staphylococcal infection is caused by methicillin-resistant Staphylococcus aureus.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Moodys
Cipla
Farmers Insurance
Deloitte
US Army
Queensland Health
Johnson and Johnson
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot